Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Corporate Venture Funds of Large Healthcare Insurance Company Strategically Invests Up to $20M in Devices, Diagnostics, Digital Health

17 Jun

An investment firm based in the USA manages corporate venture funds of a large health system and  looks to invest in companies of strategic interest to its major health plan investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Seed Fund Connected to Major China VC Invests in Companies with China Market Potential, Open to All Sectors Within Life Sciences

17 Jun

A seed fund in collaboration with a major China venture capital firm manages over $1B has both USD funds and CNY funds. The firm has invested in over 700 portfolio companies, including over 60 life science companies. While open to growth stage companies, the firm prefers to get involved as early as possible, and ideally be the first institutional investor for its portfolio company. Initial sizes of investment can largely vary, but a typical allocation size is between $1 MM to $2 MM. The firm is very entrepreneurs friendly, and invests in companies across the globe.

The firm has a general interest in Therapeutics, Digital Health, MedTech, and Diagnostics.

The firm believes that great businesses start with exceptional founding teams and values the management team of a start-up more than anything else. The firm prefers companies with a Chinese angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Fund is Most Interested in Early-Stage Therapeutics Opportunities With Broad Interests in Other Sectors, Invests Up to $20M

17 Jun

A USA based fund supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development.

The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the fund can invest directly as a Series A investment along with participation in related Series B investments.  The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Fund With Ties to China Seeks Global Early-Stage Drugs, Devices, Diagnostics, and Digital Health, with Focus in North America

17 Jun

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: Newly Established VC Invests in AI, Digital Health & Medtech Companies

15 Jun

A newly established venture capital firm based in the USA just successfully closed the first round of their fund ($20M target). The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Hot AI Mandate: Early-stage VC Focuses on AI & Data Related Technologies

15 Jun

An early-stage venture capital fund invests patient financial capital and expert human capital in entrepreneurs using data and engineering to create the future. The firm provides entrepreneurs access to a proprietary network of experts and startup resources to give them a competitive edge. The firm focuses primarily on seed to Series B investment opportunities and leads rounds when they believe can be especially helpful to a company. The firm often participates in multiple funding rounds throughout the lifecycle of a company, and always strives to support portfolio companies as they grow. The firm does not have a specific industry focus, but rather invests across verticals in companies using data science and advanced engineering to transform their industry. The fund has made just a few healthcare investments to date and historically has not led these rounds, but is investing in building out additional expertise in this area.

The firm invests across many different industries. The firm is highly interested in areas like robotics, artificial intelligence, and data science, with the key theme being strong underlying technology. In healthcare, the firm is most interested in the intersection of biology and advanced data science with an emphasis on complex solutions that fully leverage data and apply analytics as opposed to simply collecting or monitoring data. The fund also invests in more traditional healthcare IT applications on a secondary basis, as well as synthetic biology technologies. The firm tends to avoid technologies with complex regulatory pathways.

The firm will work with all companies and management teams and look to add value to by leveraging their deep technical expertise and extensive network, and place an emphasis on management teams with deep domain expertise in the specific field they are pursuing. The firm does not require any type of board representation on deals we do not lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Hot AI Mandate: CA-based VC Invests in Data-driven Healthcare/Biotech Companies Leveraging Big Data & AI/ML

15 Jun

Founded 2013, a venture capital firm is headquartered in San Francisco. The firm is investing from its most recent fund, which closed in early 2020 at $50 M. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

%d bloggers like this: